Surgical treatment for peritoneal carcinomatosis from gastric cancer.
about
Survival rate of gastric cancer in Iran; a systematic review and meta-analysisCytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and futureCytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancerBreakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanesPressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis.Regional but fatal: Intraperitoneal metastasis in gastric cancerLong term follow up and retrospective study on 533 gastric cancer cases.Transforming growth factor-beta1 signaling blockade attenuates gastric cancer cell-induced peritoneal mesothelial cell fibrosis and alleviates peritoneal dissemination both in vitro and in vivo.Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab.Lymph node, peritoneal and bone marrow micrometastases in gastric cancer: Their clinical significanceExpression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significanceThe Role of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer.Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis.Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascitesA retrospective analysis of hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis.Surgical treatment of peritoneal carcinomatosis from gastric cancer.The role of laparoscopy in peritoneal surface malignancies selected for hyperthermic intraperitoneal chemotherapy (HIPEC).Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.A systematic review and meta-analysis of gastric cancer treatment in patients with positive peritoneal cytology.Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis.Expression of vascular endothelial growth factor-C and vascular endothelial growth factor receptor-3 in esophageal squamous cell carcinoma.Oligometastatic Disease in the Peritoneal Space with Gastrointestinal Cancer.Evolution and emerging future of cytoreducxtive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: From treating the incurable to preventing recurrence.Intraperitoneal paclitaxel induces regression of peritoneal metastasis partly by destruction of peripheral microvessels.Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites.Cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion for the treatment of gastric cancer: A single-centre retrospective study.Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases.Mesothelial cells differentiate into fibroblast-like cells under the scirrhous gastric cancer microenvironment and promote peritoneal carcinomatosis in vitro and in vivo.[Peritoneal carcinomatosis].Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal goblet cell carcinomas with peritoneal carcinomatosis: results from a single specialized center.Repeat Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancy and Peritoneal Carcinomatosis.Prognostic significance, diagnosis and treatment in patients with gastric cancer and positive peritoneal washings. A review of the literature.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastrointestinal cancers: fad or standard of care?The Importance of Extensive Intraoperative Peritoneal Lavage as a Promising Method in Patients with Gastric Cancer Showing Positive Peritoneal Cytology Without Overt Peritoneal Metastasis and Other Therapeutic Approaches.Tks5 activation in mesothelial cells creates invasion front of peritoneal carcinomatosis.Clinical significance of heat shock proteins in gastric cancer following hyperthermia stress: Indications for hyperthermic intraperitoneal chemoperfusion therapy.The close relationship between heparanase and epithelial mesenchymal transition in gastric signet-ring cell adenocarcinomaExosomal miR-21-5p derived from gastric cancer promotes peritoneal metastasis via mesothelial-to-mesenchymal transition
P2860
Q26751297-C04E66A9-A492-42D5-A757-6254296DF00AQ26768296-C6D8A8A3-ACFE-44D5-BAC4-65714D646BDBQ26774538-BF565D25-DA77-4632-985C-102101562D02Q26776201-6BB452A3-8FF7-4090-B2A2-FE4A315F2435Q27313250-72D59E87-6ADA-44D2-B01E-A9A02CE62ED1Q28067269-D0363C88-BA5A-4085-81D1-9C9FD053DA00Q33680872-40AEC585-2767-47FA-BCCD-17EE9CC058F6Q34658416-1499C180-845B-4FFC-BAAD-B335580FE6DAQ35109585-15C1F9B8-4A92-4739-A023-C0283F831076Q35812530-74CD0F12-C08F-4D91-B9A7-7B32C78E4ACDQ36383251-79ACB8CA-5C34-4C25-82FD-9E27DBC6B2B8Q36758921-07420833-EFCF-4D97-9E8D-35B7BC7F1620Q36795339-931F92D7-4808-4B49-9840-84D29F56DCC5Q36946716-0680E3AA-FB48-48AB-B9C6-F27D0130FD2FQ37108203-B07EB37E-F5F6-483E-981B-5097C9D653FAQ38025112-FB39EF87-168C-466B-A19E-FFFF1CC4041DQ38027027-87BBE739-30EE-4C64-825E-D1272C85E185Q38183786-EFAF8E25-DBCC-4C5E-BA81-9C4DF197CB13Q38217046-0016C8B2-E044-4A7E-8F0E-18CF53B8BFE7Q38244051-52F8D779-6246-4CAD-8AAE-9443EE44474BQ38376244-1C131140-C5BA-41BC-955D-D21452C40DF6Q38726776-38C5B005-38DD-4D61-AF75-E4096621BB2BQ38931710-DFE39E3C-8797-419C-8ED0-ED7C2333234BQ39030522-5FD3DD53-7DE0-4022-95F8-580B45226B35Q39151711-22D2A9D8-C60F-4B0C-A00C-D42E1CC080ECQ39642640-ECCBD1F4-D1F0-4AA5-A02B-CC9E98C2EFEDQ41099259-6CBBB047-DBAC-49FC-821C-3B8730CA252EQ44539973-E55ECBD9-3F9A-4408-A98C-1766ED27CA58Q45013720-4FFA173C-2FF2-45B6-B4AA-F226999679B4Q46170838-4DF032A1-63AF-44A6-A2B3-3E5B56E2C983Q47110666-211B0387-7A88-4CE7-BC2C-77EC50D92C5BQ47749593-B89DCBDA-5EFA-476E-BD9E-3B39FF2FF694Q50202201-B7C6BE1B-13B2-4965-AEF7-9DB4EE6FFF21Q52690053-BDAEEB11-04AA-45EB-AFDA-46AC4C3CE2D2Q52839051-CADA1034-F0F6-4DCD-A635-F50D8520E37DQ54333214-997E7B14-8691-4844-AD61-20C84C93F83DQ55396753-17163789-2BD5-4F29-9A0E-51DF06BDFDF9Q58554048-22CD9EB7-CE98-47E3-B249-0589364E068DQ58699470-73F51482-5AF1-4360-9A30-5A2CBCF0824C
P2860
Surgical treatment for peritoneal carcinomatosis from gastric cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Surgical treatment for peritoneal carcinomatosis from gastric cancer.
@en
Surgical treatment for peritoneal carcinomatosis from gastric cancer.
@nl
type
label
Surgical treatment for peritoneal carcinomatosis from gastric cancer.
@en
Surgical treatment for peritoneal carcinomatosis from gastric cancer.
@nl
prefLabel
Surgical treatment for peritoneal carcinomatosis from gastric cancer.
@en
Surgical treatment for peritoneal carcinomatosis from gastric cancer.
@nl
P2093
P1476
Surgical treatment for peritoneal carcinomatosis from gastric cancer.
@en
P2093
A Mizumoto
M Ichinose
Y Yonemura
P304
P356
10.1016/J.EJSO.2010.09.006
P577
2010-10-08T00:00:00Z